FeTPPS
(Synonyms: MESO-四(4-磺酰苯基)卟吩氯化铁) 目录号 : GC43663FeTPPS是一种基于金属卟啉的ONOO⁻分解催化剂。
Cas No.:90384-82-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
FeTPPS is a metalloporphyrin-based ONOO⁻ decomposition catalyst [1]. FeTPPS catalyzes the decomposition of peroxynitrite (ONOO⁻), reducing its nitrating/oxidative damage to proteins, DNA, and lipids [2-3]. FeTPPS is primarily used in the study of oxidative stress-related disease models [4].
In cardiomyocytes, FeTPPS (50μM; 24h) reduces cell death caused by SIN-1 and SIN-1 plus H2O2 [5]. In spermatids, exposure to FeTPPS (25-50μM; 24h) ameliorates nitrosative stress [6].
In controlled cortical impact injury (CCI) mice model, FeTPPS (10mg/kg, 30mg/kg; ip; two injections) reduces secondary damage and improves neurobehavioral functions after traumatic brain injury. [7]. In a high-fat diet mice model, FeTPPS (50-60mg/kg; po; 8 weeks) treatment more than doubled the insulin-induced drop in blood glucose levels [8].
References:
[1]. Haber A, Gross Z. Catalytic antioxidant therapy by metallodrugs: lessons from metallocorroles[J]. Chemical Communications, 2015, 51(27): 5812-5827.
[2]. Uribe P, Barra J, Painen K, et al. FeTPPS, a Peroxynitrite Decomposition Catalyst, Ameliorates Nitrosative Stress in Human Spermatozoa[J]. Antioxidants, 2023, 12(6): 1272.
[3]. Zhang P, Ma L, Yang Z, et al. 5, 10, 15, 20-Tetrakis (4-sulfonatophenyl) porphyrinato iron (III) chloride (FeTPPS), a peroxynitrite decomposition catalyst, catalyzes protein tyrosine nitration in the presence of hydrogen peroxide and nitrite[J]. Journal of Inorganic Biochemistry, 2018, 183: 9-17.
[4]. Duan X, Wen Z, Shen H, et al. Intracerebral hemorrhage, oxidative stress, and antioxidant therapy[J]. Oxidative medicine and cellular longevity, 2016, 2016(1): 1203285.
[5]. Klassen S S, Rabkin S W. The metalloporphyrin FeTPPS but not by cyclosporin A antagonizes the interaction of peroxynitrate and hydrogen peroxide on cardiomyocyte cell death[J]. Naunyn-Schmiedeberg's archives of pharmacology, 2009, 379(2): 149-161.
[6]. Uribe P, Barra J, Painen K, et al. FeTPPS, a Peroxynitrite Decomposition Catalyst, Ameliorates Nitrosative Stress in Human Spermatozoa[J]. Antioxidants, 2023, 12(6): 1272.
[7]. Bruschetta G, Impellizzeri D, Campolo M, et al. FeTPPS reduces secondary damage and improves neurobehavioral functions after traumatic brain injury[J]. Frontiers in Neuroscience, 2017, 11: 6.
[8]. Duplain H, Sartori C, Dessen P, et al. Stimulation of peroxynitrite catalysis improves insulin sensitivity in high fat diet‐fed mice[J]. The Journal of physiology, 2008, 586(16): 4011-4016.
FeTPPS是一种基于金属卟啉的ONOO⁻分解催化剂 [1]。FeTPPS能催化过氧亚硝酸盐（ONOO⁻）的分解，从而降低其对蛋白质、DNA和脂质的硝化/氧化损伤 [2-3]。FeTPPS主要用于氧化应激相关疾病模型的研究 [4]。
在心肌细胞中，FeTPPS（50μM；24h）可减少SIN-1以及SIN-1与H2O2联合作用引起的细胞死亡 [5]。在精子细胞中，暴露于FeTPPS（25-50μM；24h）可改善亚硝化应激 [6]。
在受控皮质撞击损伤（CCI）小鼠模型中，FeTPPS（10mg/kg，30mg/kg；ip；两次注射）可减少脑外伤后的继发性损伤并改善神经行为功能 [7]。在高脂饮食小鼠模型中，FeTPPS（50-60mg/kg；po；8周）治疗使胰岛素引起的血糖水平下降幅度增加了一倍以上 [8]。
| Cell experiment [1]: | |
Cell lines | Cardiomyocytes |
Preparation Method | The MTT assay was used to assess cell viability. Cardiomyocytes in multiwell microtiter plates were treated for 24h with SIN-1, H2O2, FeTPPS, and/or cyclosporin A, as indicated. H2O2, 10 and 100μM, and cyclosporin A, 0.1 or 1.0μM. FeTPPS, 50μM, was chosen from concentration response data over a range. MTT dye was added to each well for the final 4h of the experiment, and solubilization solution was added to stop the reactions. As the absorbance curve of the MTT dye exhibits a linear portion ranging from 570 to 655nm, the absorbance was determined at 570nm on a multiwell plate reader using BioLinx 2.2 data capture software. Background absorbance of medium in the absence of cells was subtracted. All samples were assayed in duplicate, and the mean for each experiment was calculated. Experiments were conducted a minimum of five and a maximum of 14 times. |
Reaction Conditions | 50μM; 24h |
Applications | FeTPPS reduces cell death caused by SIN-1 and SIN-1 plus H2O2. |
| Animal experiment [2]: | |
Animal models | Controlled cortical impact injury (CCI) mice model |
Preparation Method | In this study, a traumatic brain injury (TBI) model was established in mice using the CCI method. The mice were randomly divided into four groups (n=10 in each group): TBI+Vehicle group, TBI+FeTPPS group, Sham+Vehicle group, and Sham+FeTPPS group. TBI was performed by craniotomy on the right side and using an impactor to cause moderate brain injury (impact head diameter 4mm, depth 3mm, speed 1.5m/s); the Sham group only underwent craniotomy without impact. 1h and 4h after TBI or Sham surgery, normal saline or FeTPPS (30mg/kg, intraperitoneal injection) were administered, respectively. Postoperative behavioral tests such as Morris water maze, tail suspension, rotarod, and open field were performed, and brain water content, sway test, and blood sampling for biochemical indicators were measured 24h later. |
Dosage form | 10mg/kg, 30mg/kg; ip; two injections |
Applications | FeTPPS reduces secondary damage and improves neurobehavioral functions after traumatic brain injury. |
References: | |
| Cas No. | 90384-82-0 | SDF | |
| 别名 | MESO-四(4-磺酰苯基)卟吩氯化铁 | ||
| 化学名 | Fe(III)5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato chloride | ||
| Canonical SMILES | [Cl-][Fe+3]123[N-]4C5=CC=C4C(C6=CC=C(S([O-])(=O)=O)C=C6)=C(C=C7)[N]1=C7C(C8=CC=C(S([O-])(=O)=O)C=C8)=C(C=C9)[N-]2C9=C(C%10=CC=C(S([O-])(=O)=O)C=C%10)C%11=[N]3C(C=C%11)=C5C%12=CC=C(S([O-])(=O)=O)C=C%12.[H+].[H+].[H+].[H+] | ||
| 分子式 | C44H24ClFeN4O12S4•4H | 分子量 | 1024.3 |
| 溶解度 | 5 mg/ml in water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 976.3 μL | 4.8814 mL | 9.7628 mL |
| 5 mM | 195.3 μL | 976.3 μL | 1.9526 mL |
| 10 mM | 97.6 μL | 488.1 μL | 976.3 μL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet